Finnish biotechnology company TILT Biotherapeutics (Tiltbio) has raised $25.6 million (€22.6 million) in a Series B financing. The financing will support a Phase II clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase Ib trial in melanoma in combination with TILs and other Phase Ib trials. It was […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!